Search - tctmd.com

Displaying 21 - 40 of 441

Sort: Relevancy | Date

News Conference News TCT 2022

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Shelley Wood

September 22, 2022

News Conference News ESC 2022

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

Michael O'Riordan

August 31, 2022

News Conference News ESC 2022

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Todd Neale

August 27, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

News Conference News EAS 2022

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Todd Neale

April 03, 2022

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

Caitlin E. Cox

December 28, 2021

News Daily News

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

Michael O'Riordan

December 22, 2021

News Daily News

British Medical Groups Express Concern About Inclisiran Rollout

Michael O'Riordan

December 14, 2021

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Shelley Wood

November 15, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

Shelley Wood

October 08, 2021

News Daily News

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

Michael O'Riordan

June 18, 2021

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

Advertisement

PCSK9 Inhibitors Before PCI Swiftly Lower LDL-C in ACS Patients: EPIC-STEMI

Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE

DELIVER Results, Other Analyses Bolster SGLT2 Inhibitors Across HF Spectrum

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

PACMAN-AMI: Positive Plaque Changes With Early Alirocumab Use in Acute MI

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

AHA’s 2021 Top Picks: Headway Continues to Be Made Against CVD

FDA Approves Inclisiran, a Twice-Yearly Injection to Lower LDL Levels

British Medical Groups Express Concern About Inclisiran Rollout

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

An Oral PCSK9 Inhibitor? Early Data Show Safety, Big LDL Drops

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

LDL Cholesterol-Lowering Meds Rarely Intensified: GOULD

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content